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Background: In Germany/Austria, data on medical care for cystic ﬁbrosis-related diabetes (CFRD) is limited.
Methods: Anonymized data from 659 CFRD patients were analyzed and compared to the latest ADA/CFF guidelines.
Results: Specialized diabetes clinics were attended less frequently than recommended (3.1 vs. 4.0 times yearly). 7.9% of patients had a complete
proﬁle of examinations: diabetes education (44.9%), HbA1c (88.8%), blood pressure (79.5%), BMI (86.5%), lipid status (37.5%), retinopathy
(29.9%), microalbuminuria (33.2%), and self-monitoring of blood glucose (71.6%). HbA1c and blood pressure were measured less frequently than
recommended (2.3 and 2.0 vs. 4.0 times yearly). Overall, guidelines were followed more frequently in children than adults. Contrary to
recommendations, not all patients were treated with insulin (77.2 vs. 100.0%). Insulin therapy was initiated earlier in children than adults, but there
was still a substantial delay (0.9 vs. 2.7 years after diagnosis, p b 0.001).
Conclusion: In CFRD patients studied, adherence to care guidelines was suboptimal.
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In clinical practice, treatment of cystic fibrosis-related diabetes
(CFRD) is a challenge. CFRD shares some characteristics with⁎ Corresponding author. Tel.: +49 731 5025353; fax: +49 731 5025309.
E-mail address: nicole.scheuing@uni-ulm.de (N. Scheuing).http://dx.doi.org/10.1016/j.jcf.2014.05.006
1569-1993/© 2014 European Cystic Fibrosis Society. Published by Elsevier B.V. Athe more common type 1 or type 2 diabetes, but it is a separate
clinical entity [1–3]. Hence, several aspects of medical care are
unique to CFRD. Limited guidance for CFRD treatment is
available from the German Diabetes Association [4]. A more
detailed description of the management of children and
adolescents with CFRD is given by the International Society for
Pediatric and Adolescent Diabetes [5]. In 2010, the American
Diabetes Association (ADA) in cooperation with the Cystic
Fibrosis Foundation and the Pediatric Endocrine Societyll rights reserved.
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CFRD [3].
To avoid diabetes-associated complications, adequate treat-
ment of CFRD in addition to the underlying illness is essential.
Considerable evidence from epidemiologic studies, and limited
clinical trial data, suggest an association between CFRD and
worsening nutritional status, pulmonary function, andmortality in
cystic fibrosis (CF) [6–8]. In Germany and Austria, medical care
for some patients is provided jointly by specialized CF and
diabetes clinics, while others are seen by CF teams with
pulmonology or gastroenterology expertise only. To our best
knowledge, no evaluation of the current state of medical care
specific for CFRD has been performed in Germany and Austria.
The benchmarking report from the German cystic fibrosis quality
assessment group primarily focuses on CF rather than on diabetes
in CF [9,10]. Therefore, we analyzed the current treatment for
CFRD in specialized diabetes clinics using data from a large
German/Austrian diabetes patient registry. Additionally, we
evaluated whether medical care for CFRD is in compliance with
the latest ADA/CF Foundation guidelines.
2. Materials and methods
2.1. Diabetes patient registry DPV
Since 1995, many specialized diabetes clinics from Germany
and Austria have documented prospectively demographic and
clinical data of diabetes patients in a standardized computer-based
software, called DPV (www.d-p-v.eu). Every 6 months, locally
documented data are anonymously transmitted to the University
of Ulm. To ensure data plausibility, transmitted data are verified
and reported back for corrections in case of inconsistency. For
central analyses [1,2,11] and quality assurance, all plausible data
are aggregated into a cumulative database. The DPV initiative has
been approved by the ethical committee of Ulm University.
Until March 2013, 313,973 patients with any type of
diabetes were documented in DPV by 392 centers from
Germany or Austria. For this study, patients with CFRD and
age at diabetes onset N5 years were considered. The final study
population comprised 659 CFRD patients from 119 specialized
diabetes clinics. For each patient included, datasets were
aggregated over the most recent year of care.
2.2. Medical examinations
The number of visits in diabetes clinics during the last
treatment year was evaluated and frequency and completeness
of recommended medical examinations were analyzed. We
also assessed measurement of hemoglobin A1c (HbA1c), blood
pressure, and lipids, monitoring of nutritional status and
microvascular complications (retinopathy, microalbuminuria),
participation in diabetes education programs and self-monitoring
of blood glucose (SMBG). Documentation of at least one serum
lipid value (total cholesterol, HDL, LDL, triglycerides) was
classified as lipid measurement. Attendance of at least one
diabetes education program since onset of diabetes was defined
as participation. Data on SMBG was collected by physicians onthe basis of memory blood glucose meters and patients' entries
in paper or electronic blood glucose diaries. Medical audits in a
patient were defined as ‘complete’, if all recommended
examinations were performed at least once during the recent
year of care.2.3. Nutritional status
Nutritional status was assessed by body mass index (BMI),
BMI standard deviation score (BMI-SDS), weight-SDS and
height-SDS. The latter were calculated using contemporary
national reference data from the KiGGS study. For patients
≥18 years, values were extrapolated. Underweight was defined
as BMI values below the 10th percentile for age b20 years and
for adults as BMI b19 kg/m2 [12,13]. The recommended target
is a BMI ≥50th percentile for age b20 years, and in adults a
BMI ≥22 kg/m2 for females and ≥23 kg/m2 for males [3].2.4. Metabolic control and anti-hyperglycemic therapy
Metabolic control was assessed by HbA1c. The multiple of the
mean method was applied to mathematically standardize HbA1c
values to the DCCT reference range (20.7–42.6 mmol/mol) [11].
An HbA1c ≤53 mmol/mol (≤7.0%) is recommended for most
CFRD patients [3]. Anti-hyperglycemic therapy was specified as:
i) insulin treatment (insulin only or with additional glucose
lowering agents), ii) oral anti-diabetic drug (OAD) medication and
iii) non-pharmacological treatment (dietary/physical advice only).
Insulin therapy was categorized as basal insulin only, conventional
treatment (CT, 1–3 injection time-points/day), multiple-daily in-
jections (MDI, 4–8 injection time-points/day) or continuous
subcutaneous insulin infusion (CSII). Daily insulin dose per
kilogram bodyweight was calculated.2.5. Statistical analysis
SAS version 9.3 (SAS Institute Inc., Cary, NC, USA) was
applied for data analysis. For each recommended examination,
frequency of patients with at least one measurement during the
recent treatment year was calculated. For examinations recom-
mended more than once yearly (HbA1c, blood pressure), the
respective number of measurements within the last year was
analyzed. Daily frequency of SMBGwas evaluated. Results were
displayed as mean with 95% confidence interval for continuous
variables and as percentage for dichotomous variables.
Besides the analysis of the whole study population, gender-
and age-specific analyses were carried out. Study population was
divided into two age groups: b20 (pediatric) and ≥20 years
(adult).
Continuous parameters were compared using Kruskal–
Wallis test. χ2-test was applied for dichotomous variables. A
two-sided p b 0.05 was considered significant.
All results were compared to the latest ADA/CF Foundation
clinical care guidelines for CFRD [3].
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3.1. Study population
Baseline characteristics, stratified by gender and age group,
are given in Table 1. 58.4% of study population were female
and 54.2% were younger than 20 years. Females were younger,
taller and had an earlier onset of CFRD compared to males
(p b 0.001), but otherwise there were no difference in gender at
baseline. However, several significant differences were noted
between age groups, including later age at diagnosis, longer
duration of diabetes, and better nutritional status in adults. For
59.6% of patients, medical care was provided by diabetes
clinics with N10 CFRD patients.
3.2. Medical examinations
Table 2 displays the observed frequency and number of
examinations in CFRD compared to guideline recommenda-
tions. The percentage of patients with complete examinations is
given.
In specialized diabetes clinics, patients were seen less frequently
than recommended. Only 7.9% of patients had a complete profile
of examinations. 44.9% of patients had at least one structured
diabetes education program since the onset of diabetes.
Not all patients received the recommended measurements of
HbA1c, blood pressure or lipids and the advised assessment of
nutritional status or monitoring of microvascular complications
at least once during the recent year of care. In patients with
measured HbA1c or blood pressure, the yearly number of
measurements was lower than recommended.
SMBG was performed in 71.6% of patients only. On
average, patients performing SMBG achieved the recommend-
ed frequency of 3 measurements per day.
Pediatric patients visited diabetes clinics significantly more
often than adults (Table 2). In general, the frequency and number
of recommended examinations were significantly higher in
younger patients, except for lipid measurements and retinal
examinations. Hence, medical audits were complete inTable 1
Baseline characteristics of study population.
All Male Female
Number of patients, n 659 274 385
Females, % 58.4 0.0 100.0
Age, years 22.9 (22.0–23.7) 24.0 (22.7–25.4) 22.0 (21
Age at diagnosis, years 18.8 (18.1–19.5) 19.9 (18.8–21.1) 18.0 (17
Duration of diabetes, years 4.0 (3.7–4.4) 4.1 (3.4–4.7) 4.0 (3.6–
BMI, kg·m−2 19.5 (19.2–19.8),
n = 570
19.7 (19.3–20.1),
n = 229
19.4 (19
n = 341
BMI-SDS −1.0 (−1.1 to −0.9) −1.0 (−1.2 to −0.9) −1.0 (−
Weight-SDS −1.5 (−1.7 to −1.4),
n = 597
−1.6 (−1.8 to −1.4),
n = 239
−1.5 (−
n = 358
Height-SDS −1.0 (−1.1 to −0.9),
n = 583
−1.2 (−1.3 to −1.0),
n = 236
−0.9 (−
n = 347
Underweight, % 38.4 38.9 38.1
Systemic steroids, % 19.4 20.4 18.7
Data are given as mean with 95% confidence interval or as percentage. p-Values are
mass index, SDS — standard deviation score, NS — not significant.significantly more pediatric patients than adults. Daily frequency
of SMBG was comparable between age groups.
Overall, between genders, no significant differences were
observed.
3.3. Nutritional status
BMI, BMI-SDS, weight-SDS and height-SDS for all patients
and stratified by gender or age are given in Table 1. In 36.5% of
patients weight was below the 3rd percentile for age and sex. A
height below the 3rd percentile was observed in 24.7% of
patients. Underweight was present in 38.4% of patients and was
significantly more prevalent in children and adolescents
(Table 1). 16.7% of patients achieved the recommended BMI
target (Fig. 1A). In adults, BMI achievement was significantly
more prevalent than in younger patients (Fig. 1A). Between
genders, prevalence of underweight and achievement of BMI
target did not differ (Table 1, Fig. 1A).
3.4. Metabolic control and anti-hyperglycemic therapy
Mean HbA1c during the last year of care was 55 (95% CI:
54–57) mmol/mol (7.2 (7.1–7.4)%). 58.6% of patients had an
HbA1c below or equal to the recommended target, with no
differences between genders or age groups (Fig. 1B).
Contrary to recommendations, not all patients were on insulin
(Fig. 2). 6.7% of patients were treated with OADs only and 16.1%
received non-pharmacological therapy. Anti-hyperglycemic ther-
apy did not differ significantly between genders or age groups
(Fig. 2).
Independent of gender or age group, multiple-daily injections
was the preferred insulin regimen (Table 3). 5.7% of insulin-treated
patients used basal insulin only, with no significant differences
between genders or age groups (Table 3). Daily insulin dose per kg
body weight was higher in pediatric patients than adults, but
comparable between genders (Table 3).
On average, insulin therapy was initiated 1.7 (1.4–2.0) years
after the diagnosis of diabetes. In pediatric patients, time to
insulin treatment was significantly shorter than in adults, butp-Value b20 years ≥20 years p-Value
– 357 302 –
– 60.8 55.6 NS
.0–23.0) 0.010 16.3 (16.1–16.6) 30.5 (29.3–31.8) b0.001
.1–18.9) b0.001 13.9 (13.6–14.2) 24.6 (23.3–25.8) b0.001
4.5) NS 2.4 (2.2–2.7) 6.0 (5.3–6.7) b0.001
.0–19.7), NS 18.7 (18.4–18.9),
n = 328
20.6 (20.2–21.1),
n = 242
b0.001
1.2 to −0.9) NS −1.2 (−1.3 to −1.1) −0.8 (−1.0 to −0.7) 0.004
1.7 to −1.1), NS −1.8 (−2.0 to −1.6),
n = 333
−1.2 (−1.4 to −1.0),
n = 264
b0.001
1.0 to −0.8), 0.015 −1.2 (−1.3 to −1.0),
n = 333
−0.8 (−0.9 to −0.7),
n = 250
b0.001
NS 42.1 33.5 0.037
NS 22.1 16.2 NS
given for the comparison between genders or age groups. Abbr.: BMI — body
Table 2
Medical examinations in German and Austrian patients with CFRD compared to guidelines [3].
Guideline All Male Female ⁎ b20 years ≥20 years p-Value
Visits, per year 4.0 3.1 (3.0–3.3) 3.0 (2.8–3.3) 3.2 (3.0–3.5) 3.5 (3.2–3.8) 2.7 (2.5–3.0) b0.001
At least one recommended examination
Diabetes education program since onset, % 100.0 44.9 42.3 46.8 51.8 36.8 b0.001
HbA1c, % 100.0 88.8 88.3 89.1 91.6 85.4 0.012
SMBG, % 100.0 71.6 71.2 71.9 76.8 65.6 0.002
BMI, % 100.0 86.5 83.6 88.6 91.9 80.1 b0.001
Blood pressure, % 100.0 79.5 78.5 80.3 82.4 76.2 0.049
Lipid status, % 100.0 37.5 35.8 38.7 40.1 34.4 NS
Retinopathy, % 100.0 29.9 27.7 31.4 31.4 28.1 NS
Microalbuminuria, % 100.0 33.2 32.8 33.5 37.8 27.8 0.007
Complete examinations, % 100.0 7.9 8.0 7.8 10.6 4.6 0.004
Examinations recommended more than once
HbA1c, per year 4.0 2.3 (2.1–2.4) 2.2 (2.0–2.5) 2.3 (2.1–2.5) 2.6 (2.4–2.8) 1.9 (1.8–2.1) b0.001
Blood pressure, per year 4.0 2.0 (1.9–2.2) 1.9 (1.7–2.2) 2.1 (1.9–2.3) 2.3 (2.1–2.6) 1.6 (1.5–1.8) b0.001
SMBG, per day 3.0 3.3 (3.2–3.5) 3.3 (3.0–3.5) 3.4 (3.2–3.5) 3.3 (3.1–3.5) 3.4 (3.2–3.6) NS
Data as mean with 95% confidence interval or as percentage. p-Values are given for the comparison between age groups. Abbr.: BMI— body mass index, HbA1c —
hemoglobin A1c, NS — not significant, SMBG — self-monitoring of blood glucose.
⁎ Indicate that for all comparisons between genders difference was not signiﬁcant.
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3.3) years; p b 0.001). Between genders, no difference was
observed (males vs. females: 1.9 (1.4–2.3) vs. 1.6 (1.3–2.0)
years; p = 0.48).
4. Discussion
Besides the German benchmarking reports, which focus on CF
rather than on diabetes in CF, this is the first study evaluating theFig. 1. Percentage of patients achieving target for (A) BMI or (B) HbA1c.current state of medical care specific to CFRD in Germany
and Austria. Compared to the latest ADA/CF Foundation
guidelines, our study revealed a lack of adherence to current
international clinical care guidelines for the CFRD population
studied. Multidisciplinary treatment by CF and diabetes
experts with good team communication and consistent
instructions regarding diabetes care, as well as more data
regarding benefits of CFRD treatment, might improve
adherence to published guidelines.
Manifestation of diabetes most commonly occurred at an age
where patients were at the transition from pediatric facilities to
departments of internal medicine. This might be an additional
confounder that makes adequate treatment of CFRD difficult. A
loss in transition from pediatric to adult care has been described
for patients with type 1 diabetes [14], and may play a role in
CFRD. Patients may feel more comfortable in pediatric clinics,
and thus more likely to follow recommendations, because they
have attended these centers regularly since CF diagnosis.Fig. 2. Anti-hyperglycemic therapy compared to guidelines [3].
Table 3
Type of insulin regimen and insulin dose per kilogram bodyweight in insulin-treated patients with CFRD.
All Male Female p-Value b20 years ≥20 years p-Value
Number of patients, n 509 209 300 – 281 228 –
Basal insulin only, % 5.7 5.7 5.7 NS 6.8 4.4 NS
Conventional treatment, % 40.9 42.6 39.7 NS 39.1 43.0 NS
Multiple-daily injections, % 53.6 50.7 55.7 NS 54.4 52.6 NS
CSII, % 5.5 6.7 4.6 NS 6.5 4.4 NS
Daily insulin dose, IU/kg 0.78 (0.73–0.83),
n = 482
0.74 (0.66–0.82),
n = 192
0.81 (0.75–0.87),
n = 290
NS 0.85 (0.78–0.92),
n = 273
0.69 (0.62–0.76),
n = 209
0.002
Data are given as mean with 95% confidence interval or as percentage. p-Values are given for the comparison between genders or age groups. Abbr.: CSII —
continuous subcutaneous insulin infusion, NS — not significant.
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diabetes as CF comorbidity than specialists in internal medicine.
In German/Austrian diabetes care centers, more than half of
patients had never participated in a structured diabetes education
program since onset of diabetes. This might be due to concerns
about bacterial colonization or insufficient time as multiple
CF-related therapies are required. Additionally, education topics
differ between CFRD and type 1 or type 2 diabetes (e.g. low
rate of ketoacidosis, high-calorie diet, relevance of microvas-
cular complications vs. risk of lung infections). In CFRD, an
individualized education with CF-specific training material is
necessary. In contrast to other types of diabetes, the underlying
disease in CFRD is life-threatening; hence, psychological
counseling is also different.
Even though HbA1c, BMI and blood pressure were measured
at least once during the recent year of care in the majority of
patients, lipid status and microvascular complications were
monitored in a minority of patients only. Perhaps there are
concerns or doubts about the utility of these measurements in
long-term outcomes of CF patients, including the lack of strong
evidence behind some of the guideline recommendations in the
CFRD population. In the case of lipid and retinopathy screening,
logistical implications may play a role (e.g. fasting conditions for
lipid measurement, or specialist referral for retinopathy screen-
ing). In general, pediatric patients received medical examinations
more often than adults. Children and adolescents may visit
medical centers more frequently than adults. Moreover, some
examinations (like BMI and lipid status) may seem less important
in adulthood, when little year-to-year variation is expected.
HbA1c and blood pressure were measured only half as often as
recommended. These measurements may also be performed by
CF clinics and thus intentionally not duplicated in specialized
diabetes clinics. Nevertheless, diabetes clinics should be aware of
the results to include them in their longitudinal documentation for
appropriate long-term care. Recently, data documentation in the
DPV software has been expanded to include lung function
parameters (FEV1, vital capacity) and type of CFTR mutation. In
parallel, the German CF quality assessment group added the
documentation of further diabetes-related parameters to their CF
registry [9,10]. A more interdisciplinary approach, as recom-
mended by guidelines [3], may facilitate improved screening and
treatment.
About one third of patients had a metabolic control worse
than recommended. In type 1 or type 2 diabetes, the HbA1ctarget is also not achieved by many patients [15–17]. In the
latest National Health and Nutrition Examination Survey, only
52.5% of adults with diabetes had an HbA1c b7% [18]. HbA1c
is the preferred indicator of glycemic control in type 1 or type 2
diabetes [19]. In CFRD, HbA1c values are often falsely low due
to an increased hemolysis in CF [20,21]. In addition, acute and
chronic infections may contribute to higher values. The degree
of metabolic control documented in this study is ‘optimistic’.
Assuming that at least some HbA1c values were falsely low, the
true number of patients with poor metabolic control is likely
higher than the one-third estimate mentioned. As in other forms
of diabetes, an elevated HbA1c in CFRD is associated with an
increased risk of microvascular complications [22]. Hence,
monitoring HbA1c regularly is appropriate in order to observe
trends in glycemic control [3].
Loss of calories through malabsorption and high resting
energy expenditure often contribute to a poor nutritional status in
CFRD. Less than 20% of patients had a BMI equal to or above
the target. Compared to adult CF patients (≥18 years) from the
German CF benchmarking reports in 2001 and 2008 [9,10], our
adult CFRD patients (≥20 years) revealed on average a
comparable BMI, but a lower height-SDS. Weight-SDS and
height-SDS of our pediatric CFRD patients (b20 years) were
lower than in pediatric CF patients (b18 years) from the
benchmarking report in 2001 [9]. A poor nutritional status is
associated with declining lung function and increased mortality.
Especially in pediatric patients, additional energy requirement for
growth should be kept in mind. In CFRD, different dietary advice
is necessary compared to type 1 or type 2 diabetes.
The only recommended pharmacologic therapy for CFRD is
insulin [3]. OADs are not advised, because they showed less
effectiveness and are less well studied in CFRD [3]. As shown by
this study, in clinical practice not all patients are treated with
insulin. In a questionnaire survey among UK CF centers, insulin
was the preferred treatment modality in 97% of investigated
centers [23]. In contrast to our analysis, pediatric centers in the
UK used OADs less frequently than departments of internal
medicine.
Our data further indicate that insulin therapy was not initiated
immediately after the diagnosis of diabetes in all patients.
However, an earlier start of insulin therapy in younger patients
compared to adults was observed. There is little evidence on the
optimal insulin regimen in CFRD [3]. In our study, the majority
of patients preferred multiple-daily injections. Improvements of
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decreasing mortality were reported as benefits of insulin therapy
in CFRD [24–27].
The reasons for withholding insulin treatment remain unclear.
Patients in an early stage of CFRD may not be persistently
hyperglycemic. Furthermore, the start of insulin treatment might be
considered as an additional burden for patients, who already
require multiple CF-related therapies and often face social
challenges around the age of CFRD onset (e.g. increasing
autonomy, moving out of the family home, starting work). By
comparison, oral anti-diabetic treatment or lifestyle intervention
may be less complex or labor-intensive for both providers and
patients. In addition, the fear of insulin-induced hypoglycemiamay
play a role. In CFRD, insulin-induced hypoglycemia may be
aggravated by decreased hepatic glycogen stores and impaired
pancreatic glucagon secretion. Moreover, screening practices for
CFRD and administration of insulin therapy in CFRD with and
without fasting hyperglycemia have changed over the years [3,28].
This may account also for the longer delay in instituting insulin
therapy in adults compared to children, who presumably were
diagnosed more recently. Nowadays, an oral glucose tolerance test
is recommended for every CF patient aged ≥10 years and all
CFRD patients, independent of fasting blood glucose, should
receive insulin [3]. In amulticenter study, conducted between 2001
and 2010, serial oral glucose tolerance tests were performed by 43
specialized CF centers from Germany and Austria [29], indicating
that regular screening is becoming more widespread in this region.
Strengths of our study include its large number of patients
from various parts of Germany/Austria, the standardized
documentation of clinical data by trained medical staff and
the rigorous analysis of a large medical database rather than
relying on questionnaires. A limitation is that only specialized
diabetes centers were included. Indeed, CFRD patients also
visit CF specific clinics. Therefore, the total number of visits to
medical care centers is probably higher than documented in our
study. Nevertheless, as diabetes-specific examinations likely
are completed less often in CF clinics compared to specialized
diabetes centers, the true adherence to guidelines in CFRD
patients might be even lower than reported here.
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Kinderklinik MHH, Heidelberg Uni-Kinderklinik, Heilbronn
Innere Klinik, Hinrichsegen-Bruckmühl Diabetikerjugendhaus,
Homburg Uni-Kinderklinik Saarland, Idar Oberstein Innere,
Innsbruck Universitätskinderklinik, Jena Uni-Kinderklinik,
Karlsruhe Städtische Kinderklinik, Kassel Klinikum Kinder-
und Jugendmedizin, Kassel Städtische Kinderklinik, Kiel
Städtische Kinderklinik, Kiel Universitäts-Kinderklinik, Kirchen
DRK Klinikum Westerwald Kinderklinik, Kirchheim-
Nürtingen Innere, Klinikum Hildesheim GmbH Innere,
Koblenz Kinderklinik Kemperhof, Krefeld Innere Klinik,
Krefeld Kinderklinik, Köln Kinderklinik Amsterdamerstrasse,
Köln Uni-Kinderklinik, Leipzig Uni-Kinderklinik, Lilienthal
Schwerpunktpraxis, Linz Landes-Kinderklinik, Ludwigshafen
Kinderklinik St. Anna-Stift, Ludwigshafen diabetol. SPP,
Lünen Klinik am Park, Magdeburg Uni-Kinderklinik, Mainz
Uni-Kinderklinik, Mannheim Uni-Kinderklinik, Memmingen
Kinderklinik, München-Schwabing Kinderklinik, Münster Uni-
Kinderklinik, Neumarkt Innere, Neunkirchen Marienhausklinik
Kohlhof Kinderklinik, Neuwied Kinderklinik Elisabeth, Nidda
Bad Salzhausen Klinik Rabenstein/Innere-2 Reha, Oldenburg
Kinderklinik, Oldenburg Schwerpunktpraxis, Osnabrück
Christliches Kinderhospital, Paderborn St. Vincenz Kinderklinik,
Passau Kinderklinik, Ravensburg Kinderklink St. Nikolaus,
Regensburg Kinderklinik St. Hedwig, Rosenheim Innere Medizin,
Rosenheim Schwerpunktpraxis, Rostock Uni-Kinderklinik,
Saaldorf-Surheim Diabetespraxis, Salzburg Kinderklinik,
Schwerin Innere Medizin, Schwerin Kinderklinik, Siegen
Kinderklinik, Singen-Hegauklinik Kinderklinik, Stuttgart
Olgahospital Kinderklinik, Sylt Rehaklinik, Tettnang Innere
736 N. Scheuing et al. / Journal of Cystic Fibrosis 13 (2014) 730–736Medizin, Traunstein diabetol. Schwerpunktpraxis, Trier
Kinderklinik der Borromäerinnen, Tübingen Uni-Kinderklinik,
Ulm Endokrinologikum, Ulm Uni-Kinderklinik, Vechta
Kinderklinik, Weingarten Kinderarztpraxis, Wien Uni-Kinder
klinik, Wiesbaden Kinderklinik DKD, Wilhelmshaven
Reinhard-Nieter-Kinderklinik, Worms Kinderklinik, Wuppertal
Kinderklinik.References
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